Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM Announces Opening of New cGMP Biopharmaceutical Manufacturing Operation

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Company announced that their new cGMP custom biopharmaceutical manufacturing 'biologics plant of the future' will open in Brisbane, Australia, in June 2013.

The DSM facility was built with cooperation from the Queensland and Commonwealth Governments of Australia. Karen King, President of DSM Biologics, the biopharmaceutical manufacturing business of DSM Pharmaceutical Products, stated, “We are thrilled to announce the June opening our of new cGMP facility in Brisbane. This operation combines DSM's twenty five years of experience and high quality track record in mammalian cell culture manufacturing with a state-of-the-art commercial and development facility. Our partnership with the Government of Queensland and the Commonwealth of Australia has led to this important addition to the Australian biotechnology industry and will be a key contributor to the entire Asia-Pacific region."

Alexander Wessels, President and CEO of DSM Pharmaceutical Products commented, "We are particularly delighted to be bringing our world-class operating ability to the Asia-Pacific region, an important growth area in our strategic development in the biopharmaceutical field; to provide further value to our customers in this region and around the globe." Australia has a vibrant biotechnology industry, but previously had no custom mammalian-based biopharmaceutical manufacturing operation in country. The Queensland Government formed BioPharmaceuticals Australia (BPA), who has partnered with DSM to bring this new facility and operation to Brisbane.

David Hughes, CEO of BioPharmaceuticals Australia said, "The opening of this facility satisfies a national capability gap. Our partnership gives Australia and the wider region access to DSM's extensive experience, expertise and ongoing commitment to developing improved bioprocessing technologies. DSM's operations are a good strategic fit with Australia's existing capabilities and we are already seeing flow-on benefits from local alliances".

The DSM operation will provide cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing. DSM Biologics operates with all standard technologies and also has a portfolio of proprietary technologies for the optimization of biopharmaceutical manufacturing, reducing the cost and risk of mammalian cell culture. The facility has an annual output capability of 500kg and has expansion space available for further capacity utilization.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM Announces License Agreement with Amgen
License agreement for use of DSM's XD® cell culture patents.
Tuesday, January 15, 2013
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
How Prions Kill Neurons: New Culture System Shows Early Toxicity to Dendritic Spines
Boston University researchers have developed a cell culture system to study prions.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Bio-Mimicry Method For Preparing & Labeling Stem Cells Developed
Method allows researchers to prepare mesenchymal stem cells and monitor them using MRI.
Stem Cell Advance Could Be Key Step Toward Treating Deadly Blood Diseases
UCLA scientists get closer to creating blood stem cells in the lab.
Harnessing Engineered Slippery Surfaces For Tissue Repair
A new method could facilitate the transfer of intact regenerating cell sheets from the culture dish to damaged tissues in patients.
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Brazilian Zika Virus Strain Causes Birth Defects in Experimental Models
First direct experimental proof of causal effect, researchers say.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!